Efstathios Kastritis, Ioanna Dialoupi, Maria Gavriatopoulou, Maria Roussou, Nikolaos Kanellias, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Elektra Papadopoulou, Dimitrios C Ziogas, Kimon Stamatelopoulos, Efstathios Manios, Argyrios Ntalianis, Evangelos Eleutherakis-Papaiakovou, Asimina Papanikolaou, Magdalini Migkou, Aristea-Maria Papanota, Harikleia Gakiopoulou, Erasmia Psimenou, Maria Irini Tselegkidi, Ourania Tsitsilonis, Ioannis Kostopoulos, Evangelos Terpos, Meletios A Dimopoulos
Bortezomib and dexamethasone with cyclophosphamide (CyBorD) or melphalan (BMDex) are commonly used primary treatments for light-chain (AL) amyloidosis, but limited data exist on bortezomib with immunomodulatory drug combinations. We report our experience with primary therapy with a bortezomib, lenalidomide, and dexamethasone (VRD) "light" regimen in 34 consecutive patients with AL amyloidosis. The majority (79%) had cardiac involvement, 15% and 23% were Mayo stage 3A and 3B, respectively, and 54% had renal involvement...
October 22, 2019: Blood Advances